Seattle, WA, United States of America

Michael A Schoenborn

This inventor holds 2 USPTO granted patents. Top assignee: Immunex Corporation. Active years: 1990-1993.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 1990-1993

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Michael A. Schoenborn: Innovator in Bovine Interleukin Research

Introduction

Michael A. Schoenborn is a notable inventor based in Seattle, WA (US). He has made significant contributions to the field of biotechnology, particularly in the area of bovine interleukin research. With a total of 2 patents to his name, Schoenborn's work has had a meaningful impact on the scientific community.

Latest Patents

Schoenborn's latest patents include groundbreaking work on bovine interleukin-1.alpha. His patents detail the cloning and expression of DNA segments encoding bovine IL-1.alpha., as well as processes for producing purified bovine IL-1.alpha. as a product of recombinant cell culture. These innovations are crucial for advancing research in immunology and veterinary medicine.

Career Highlights

Throughout his career, Schoenborn has been associated with Immunex Corporation, where he has furthered his research and development efforts. His work has contributed to the understanding of immune responses in cattle, which can have implications for both animal health and agricultural practices.

Collaborations

Schoenborn has collaborated with esteemed colleagues such as Douglas Pat Cerretti and Charles R. Maliszewski. These partnerships have enhanced the scope and impact of his research, fostering a collaborative environment that promotes innovation.

Conclusion

Michael A. Schoenborn's contributions to the field of biotechnology, particularly through his patents on bovine interleukin-1.alpha., highlight his role as a significant inventor. His work continues to influence research and development in immunology and veterinary science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…